Apollo AyurVAID, India’s leading NABH-accredited precision Ayurveda hospital network, has announced its strategic entry into the Ayurveda product space—marking a major diversification beyond clinical services. The new product portfolio includes classical formulations, over-the-counter (OTC) products, and medical foods, targeting India’s rapidly expanding Ayurveda market, currently valued at approximately ₹60,000 crore and growing at over 16% annually.
Setting a new benchmark for safety and transparency in the industry, Apollo AyurVAID’s product range features clinically proven formulations tested and certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial load, and other relevant safety parameters. Each product comes with a QR code on the packaging, allowing consumers to verify lab test results—an industry first that underlines the company’s commitment to trust, safety, and evidence-based Ayurveda.
“This expansion into clinically validated Ayurveda products marks a transformative moment in traditional medicine,” said Dr. Preetha Reddy, Executive Vice Chairperson of Apollo Hospitals and Chairperson of Apollo AyurVAID. “It is a natural progression of our precision Ayurveda approach, blending innovation with ancient wisdom to shape the future of integrative healthcare.”
Rajiv Vasudevan, Founder, MD & CEO of Apollo AyurVAID, added, “With two decades of clinical leadership, we are now extending our credibility into the consumer space. This new vertical strengthens our care continuum while unlocking scalable growth opportunities. We are targeting Rs. 500 crore in revenues from the product portfolio within five years.”
The Ayurveda products division is being launched as a separate business unit within Apollo AyurVAID, remaining anchored in its clinical-outcomes-driven care model. While classical formulations will be prescribed, OTC and medical food products will be widely available through Apollo AyurVAID’s hospitals and clinics, Apollo Pharmacies, Apollo 24|7, the company’s website, and top e-commerce platforms.
Innovative product formats—such as creams, transdermal patches, and essential extracts—will cater to distinct consumer needs across women’s health, elder care, stress, sleep, skin, and pain management. The range will include AyurVAID-branded classical and OTC products, and a line of dietary supplements under the AvestaAyurVAID brand, co-developed with Avesthagen Limited using scientifically validated botanical actives.
The company is also expanding its hospital footprint, aiming to add nine new centers in an asset-light model and scale to 350 beds this fiscal. Apollo AyurVAID expects to treat over 50,000 patients and cross the Rs. 100 crore annual revenue mark by mid-next year—setting a new precedent in the Ayurveda services sector.
“This is just the beginning of our journey to take Apollo AyurVAID’s trusted, precision Ayurveda to every corner of India and beyond,” Vasudevan said.